NCT00613652View on ClinicalTrials.gov

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
CancerTumorsCarcinoma
Interventions
DRUG

AZD4877

10 mg IV (3 weeks treatment 1 week rest)

Trial Locations (1)

Unknown

Research Site, Fukuoka

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY